DOCSLIB.ORG

7.5 Mg/Ml Solution for Injection Piritramide Read All of This Leafle

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
7.5 Mg/Ml Solution for Injection Piritramide Read All of This Leafle PACKAGE LEAFLET: INFORMATION FOR THE USER Piritramide [MAH] 7.5 mg/ml solution for injection Piritramide Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Piritramide [MAH] is and what it is used for 2. What you need to know before you are given Piritramide [MAH] 3. How to use Piritramide [MAH] 4. Possible side effects 5. How to store Piritramide [MAH] 6. Contents of the pack and other information 1. WHAT PIRITRAMIDE [MAH] IS AND WHAT IT IS USED FOR Piritramide [MAH] contains the active substance piritramide. It belongs to a group of medicines called opioid analgesics (strong painkillers). Piritramide [MAH] is used to relieve severe to strongest pain. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN PIRITRAMIDE [MAH] Do not use Piritramide [MAH]: - If you are allergic to piritramide or any of the other ingredients of this medicine (listed in section 6). - If you suffer from severely impaired consciousness from which you cannot be roused even by external stimuli. - If you have problems with breathing (respiratory depression). Warnings and precautions Talk to your doctor or pharmacist before you are given Piritramide [MAH] - If you have suffer from seizures (such as epileptic fits) - If you suffer from alcoholism - If you have head injuries - If you have an increased brain pressure - If you have an enlarged prostate (prostatic hypertrophy) - If you are in shock - If you have a severely slowed heart beat (bradycardia) or irregular heart beat (bradyarrhythmia). - If you are taking medicines that act on the brain function [e.g. alcohol, sleeping tablets (barbiturates, hypnotics), tranquillisers (certain benzodiazepines)] - If you have an under active thyroid (hypothyreosis) - If you have a decreased function of the adrenal cortex (adrenal cortex insufficiency) - If you have an impaired breathing function - If you have impaired liver or kidney function - If you are severely underweight (cachectic) or weak or if you are elderly. Special care should be taken when using Piritramide [MAH] – If you have a tumour of the adrenal gland (phaeochromocytoma) – If you have a partial or complete blockade of the bowel and/or inflammatory bowel disease – If you have an impaired function of the gall bladder (biliary impairment) – If you have an inflamed pancreas (pancreatitis) – In children aged under 1 year Blood pressure may fall after administering Piritramide [MAH]. This may exceed the norm if you have insufficient fluid in your circulatory system or were simultaneously given medicines that have a depressant effect on the central nervous system. Piritramide [MAH] can cause physical and psychological dependence. The risk of dependence usually increases with the length of use and with increasing doses. Over time, your body may develop a tolerance to the active substance so that a higher dose is required to achieve the same pain-relieving effect. CNS depressant effects and / or respiratory depression including respiratory depression and respiratory failure may occur in patients receiving Piritramide [MAH]. Medicine that blocks the effect of Piritramide [MAH] (opioid antagonist) should be available for immediate use. Due to the long duration of action of piritramide repeated administration of the antagonist may be necessary. Qualified personnel and adequate facilities should be available for monitoring and ventilation of patients administered high doses of Piritramide [MAH]. Discontinuing the medicine, substituting a milder opioid or administering a medicine that counteracts the effect of Piritramide [MAH] may trigger withdrawal symptoms such as balance disorders, tremor, anxiety, vomiting, diarrhoea and/or high blood pressure. Other medicines and Piritramide [MAH] Concomitant use of piritramide and sedative medicines such as benzodiazepines or related drugs increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening. Because of this, concomitant use should only be considered when other treatment options are not possible. However if your doctor does prescribe piritramide together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking, and follow your doctor’s dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms. Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is especially important with the following medicines: - central nervous system depressants (medicines used to treat anxiety, calm you down or put you to sleep such as barbiturates, phenothiazines, inhalational anaesthetics) - monoamine oxidase inhibitors – MAOIs (medicines prescribed to treat depression). Administration of MAOIs must be stopped at least 10 days prior to the treatment with piritramide. - pentazocine (painkiller) - medicines that inhibit the degradation of piritramide (so-called CYP3A4 inhibitor). It may be necessary to reduce the initial dose of Piritramide [MAH]. Piritramide [MAH] with food, drink and alcohol Please tell your doctor if you consumed alcohol before receiving this medicine. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before this medicine is administered to you. Pregnancy Piritramide [MAH] should not be administered during pregnancy or lactation, unless clearly necessary. Repeated administration of this medicine during pregnancy may cause dependence and withdrawal symptoms in a newborn baby. Lactation It is recommended that you stop breast-feeding for 24 hours after Piritramide [MAH] has been given to you. Driving and using machines This medicine can make dizzy and drowsy. Therefore, you must not drive or operate any tools or machines for at least 24 hours. 3. HOW TO USE PIRITRAMIDE [MAH] Piritramide [MAH] is given to you by your doctor or healthcare professional. Use in adults - A usual single dose is 15-30 mg if this medicine is given into a muscle or under the skin. - Single doses of 7.5-22.5 mg will be slowly given into a vein (10 mg per minute) (only when a particularly rapid effect is required). Intramuscular, subcutaneous and intravenous single doses can be repeated usually after 6-8 hours if the analgesic effect is fading. Dose escalation of Piritramide [MAH] should be handled carefully to avoid an accumulation of piritramide that may increase the risk of respiratory depression. It may take up to 24 hours until a patient benefits from full analgesic effect of a piritramide dose. Use in children - A usual single dose is 0.05-0.2 mg per kg body weight if this medicine is given into a muscle or under the skin. - A usual single dose should be 0.05-0.1 mg per kg body weight if Piritramide [MAH] is given into a vein (only when a particularly rapid effect is required). Use in special patient groups In severely underweight (cachectic), weak or elderly patients, patients with impaired liver or kidney function the initial dose should be reduced. Method of administration This medicine can be given as an injection into a muscle (intramuscular use), under the skin (subcutaneous use) or into a vein (intravenous use). If you are given more Piritramide [MAH] than you should Since Piritramide [MAH] will usually be given to you under carefully controlled conditions, it is unlikely that you will be given too much or that you will miss a dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4. POSSIBLE SIDE EFFECTS Like all medicines, Piritramide [MAH] can cause side effects, although not everybody gets them. The following side effects have been reported and are listed in order of decreasing frequency: Very common: may affect more than 1 in 10 people - rapid heartbeat - low blood pressure in tests Common: may affect up to 1 in 10 people - dizziness (vertigo) - severe light-headedness (stupor) - drowsiness - nausea - vomiting - retching - pallor Uncommon: may affect up to 1 in 100 people - dependency on the medicine - headache - fall in blood pressure - increased sweating - low respiration rate Not known: frequency cannot be estimated from the available data – severe allergic reactions (anaphylaxis, anaphylactic shock) – withdrawal symptoms after discontinuing the medicine (such as rapid heart rate, vomiting, muscle pain and sweating) – unconsciousness – constriction of the pupils – slow heart beat (bradycardia) – blue discolouration of the skin due to oxygen deficiency (cyanosis) – breathing problems (breathlessness, shallow breathing, respiratory arrest) – allergic skin inflammation – itching – reactions at the injection site – severe asthma attacks (status asthmaticus) – spasms of the bronchial muscles Patients who are on Piritramide [MAH] may experience an absence of bowel movements which can lead to constipation. With other opioids there have also been reports of dry mouth, increased muscle tone in urinary bladder, gall bladder and pancreas and, in rare cases, difficulties in passing water. Reporting of side effects If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine. 5. HOW TO STORE PIRITRAMIDE [MAH] Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and label after “EXP:”. The expiry date refers to the last day of that month.
Load more

Recommended publications
  • Pain Management After Elective Shoulder Surgery: a Randomized Quantitative Study Comparing Hydromorphone with Piritramide
    Case Report J Anest & Inten Care Med Volume 9 Issue 4 - October 2019 Copyright © All rights are reserved by Hermann Prossinger DOI: 10.19080/JAICM.2019.09.555768 Pain Management After Elective Shoulder Surgery: A Randomized Quantitative Study Comparing Hydromorphone With Piritramide Boesmueller S1, Gerstorfer I1, Steiner M1, Prossinger H2*, Fialka C1 and Steltzer H1, 3 1AUVA Meidling, Austria 2Department for Evolutionary Anthropology, University of Vienna, Austria 3Sigmund Freud University, Austria Submission: September 25, 2019; Published: October 11, 2019 *Corresponding author: Hermann Prossinger, Department for Evolutionary Anthropology, Faculty of Life Sciences, University of Vienna, Vienna, Austria Abstract Background: Postoperative pain management plays an important role in elective shoulder surgery. Several methods have been investigated so far. The aim of this randomized quantitative study is to compare two frequently used postoperative pain regimes (hydromorphone versus piritramide) regarding onset and duration after the effectiveness of the single-shot interscalene block has diminished. Methods: All patients who underwent elective shoulder surgery at our institution agreed to participate in this study. Upon admission patients were assigned membership to group A (hydromorphone) or group B (piritramide) according to the patient number (which ensured randomization). Pain assessment was performed using the numeric rating scale (NRS). For statistical analyses the techniques of maximum likelihood (ML) estimation were used. Results: Of the 48 patients aged 18–89 years included in this study, 25 were in group A and 23 in group B. Of these 48, 21 in each group registered pain levels above threshold at least once. Shoulder surgery was performed 45 times in an arthroscopic and 3 times in an open technique.
    [Show full text]
  • Evidence Review F: Opioids for Pain Relief After Caesarean Birth
    National Institute for Health and Care Excellence FINAL Caesarean birth [F] Opioids for pain relief after caesarean birth NICE guideline NG192 Evidence review March 2021 Final This evidence review was developed by the National Guideline Alliance which is a part of the Royal College of Obstetricians and Gynaecologists FINAL Contents Disclaimer The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian. Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties. NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive.
    [Show full text]
  • Chromatography Including Electrophoresis and Other Separation Methods
    15SIO 06£ i 36 j 6 VOL. 610 NO.2 JUNE 12, 1992 THIS ISSUE COMPLETES VOL. 610 Bibliography Section JOURNAL OF CHROMATOGRAPHY INCLUDING ELECTROPHORESIS AND OTHER SEPARATION METHODS EDITORS U. A. Th. Brinkman (Amsterdam) R. W. Giese (Boston, MA) J. K. Haken (Kensington, N.S.W.) K. Macek (Prague) L. R. Snyder (Orinda, CA) EDITORS. SYMPOSIUM VOLUMES. E. Heftmann (Orinda. CAl. Z. Deyl (Prague) EDITORIAL BOARD D. W. Armstrong (Rollo. MO) W. A. Aue (Holifo,) P. Botek (8.00) A. A. Boulton (Saskatoon) P. W. Cmr (Minneopolis. MN) N. H. C. Cooke (San Ramon. CAl V. A. Davankov (Moscow) Z. Deyl (Progue) S. Dilli (Kl~nsington. N.S.W.) F. Ern! (Basle) M. B. Evans (Hatfield) J. L. Glojcl, (N. Billerico. MA) G. A. Guiochon (Knoxville, TN) P. R. Haddod (Kensington. N.S.W.) I. M. Hais (Hradec Kralove) W. S. Hancock (San FranCISCo. CAl S. Hjerten (Uppsalo) Cs. Horvinh (New Haven. CT) J. F. K. Huber (Vienna) K.·P. Hupe (Woldbronn) T. W. Hutchens (Houston. IX) J. Jonak (B.oo) P. Jandera (Pardubice) B. L. Kmger (B05<on. MA) J. J. Kirkland (Wilmington. DE) E. sz. Kovats (Lausanne) A. J. P. Mortin (Cambridge) L. W. McLoughlin (Chestnut Hill. MA) E. D. Morgan (Keele) J. O. Pearson (KrJlamazoo, MI) H. Poppe (Amsterdam) F. E. Regnier (West Lafayette. IN) P. G. Righetti (Milan) P. Sclloenmakers (Eindhoven) R. Schwarzenbach (Dubendor!) R. E. Shoup (West Lafayette. IN) A. M. Siouf!i (Mo,seille) D. J. Strydom (Boston. MA) N. Tonaka (Kyoto) S. Terabe (Hyogo) K. K. Unger (Mainz) R. Verpoorle (Leiden) Gy.
    [Show full text]
  • Narcotic Drugs Stupefiants Estupefacientes
    E/INCB/1993/21Supp.6 INTERNATIONAL NARCOTICS CONTROL BOARD - VIENNA SUPPLEMENT No. 6 TO NARCOTIC DRUGS ESTIMATED WORLD REQUIREMENTS FOR 1994 STATISTICS FOR 1992 ESTIMATES UPDATED AS OF 30 JUNE 1994 ORGANE INTERNATIONAL DE CONTROLE DES STUPEFIANTS - VIENNE SUPPLEMENT N° 6 A r STUPEFIANTS EVALUATIONS DES BESOINS DU MONDE POUR 1994 STATISTIQUES POUR 1992 EVALUATIONS A JOUR AU 30 JUlN 1994 JUNTA INTERNACIONAL DE FISCALlZACION DE ESTUPEFACIENTES - VIENA SUPLEMENTO N.o 6 A ESTUPEFACIENTES PREVISIONES DE LAS NECESIDADES MUNDIALES PARA 1994 ESTADfsTICAS PARA 1992 PREVISIONES ACTUALlZADAS AL 30 DE JUNIO DE 1994 ~If..~~ ~ ~-tR UNITED NATIONS - NATIONS UNIES - NACIONES UNIDAS 1994 The updating of Table A is carried out by means of 12 monthly supplements. In order to facilitate the task of the exporting countries, the 12 supplements now report all the totals of the estimates and not only the amended data. In this way, each supplement cancels and replaces the published table in its entirety. In order to accelerate the transmission of the supplements to the competent national authorities, the 12 supplements will appear in English. Reading of these 12 supplements in French and Spanish may be facilitated by consulting the indexes of countries and territories and of narcotic drugs appearing in the annual publication. La mise El jour du tableau A s'effectue au moyen de douze supplements mensuels. Afin de faciliter la tache des pays exportateurs, les douze supplements contiennent tous les totaux des evaluations et non pas seulement les chiffres qui ont ete modifies. De celte maniere, chaque supplement annule et remplace entierement le tableau publie.
    [Show full text]
  • Tramadol: a Review of Its Use in Perioperative Pain
    Drugs 2000 Jul; 60 (1): 139-176 ADIS DRUG EVA L U AT I O N 0012-6667/00/0007-0139/$25.00/0 © Adis International Limited. All rights reserved. Tramadol A Review of its Use in Perioperative Pain Lesley J. Scott and Caroline M. Perry Adis International Limited, Auckland, New Zealand Various sections of the manuscript reviewed by: S.R. Abel, Indiana University Medical Centre, Indianapolis, Indiana, USA; S.S. Bloomfield, University of Cincinnati, Cincinnati, Ohio, USA; J.E. Caldwell, Department of Anesthesia, University of California, San Francisco, California, USA; K.A. Lehmann, Institute of Anaesthesiology and Intensive Care Medicine, University of Cologne, Cologne, Germany; L. Radbruch, Institute of Anaesthesiology and Intensive Care Medicine, University of Cologne, Cologne, Germany; K. Szymanski, Indiana University Medical Centre, Indianapolis, Indiana, USA; P. Tarkkila, Department of Anaesthesia, Helsinki University Centre Hospital, Helsinki, Finland; C.H. Wilder-Smith, Gastrointestinal Unit and Nociception Research Group, Berne, Switzerland. Data Selection Sources: Medical literature published in any language since 1993 on tramadol, identified using AdisBase (a proprietary database of Adis International, Auckland, New Zealand) and Medline. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: AdisBase search terms were ‘tramadol’ or ‘CG-315’ or ‘CG-315E’ or ‘U-26225A’. Medline search terms were ‘tramadol’. Searches were last updated 26 May 2000. Selection: Studies in patients with perioperative moderate to severe pain who received tramadol. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred.
    [Show full text]
  • Opioid Analgesics and the Gastrointestinal Tract
    NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #64 Carol Rees Parrish, R.D., M.S., Series Editor Opioid Analgesics and the Gastrointestinal Tract Lingtak-Neander Chan Opioids have been used to manage pain and other ailments for centuries. The consti- pating effects of opioid analgesic agents are well known and can be used to manage severe diarrhea and control high output ostomies. Loperamide, diphenoxylate, and difenoxin are currently the only opioid-derivatives approved by the FDA for treating diarrhea. Drug-drug interactions and end organ dysfunction may exacerbate systemic side effects of these drugs. In patients who have failed to respond to these agents, other systemic opioids may be considered. The goal of therapy to control gastrointestinal secretion should be to use the lowest effective dose with minimal side effects. Careful monitoring for systemic side effects during the initiation and dose titration phase are crucial to minimize the risks associated wtih opioid use. INTRODUCTION Sumerian clay tablets inscribed in Cuneiform script he term “opioid” refers to a large group of com- about 3000 B.C. Opium was probably used as an pounds and chemicals that share the characteris- euphoriant in religious rituals by the Sumerians (1,2). Ttics of opium. Opium, from the Greek word During the Middle Ages, after opium was introduced “opos” for juice, refers to the liquid collected from the to Asia and Europe, more extensive documentation of unripe seed capsule of Papaver somniferum L., also opium use became available. It wasn’t until 1805, that known as opium poppy. Opium has been used for med- a young German apothecary named Friedrich Wilhelm icinal purposes for centuries.
    [Show full text]
  • PACKAGE LEAFLET: INFORMATION for the USER Piritramide [MAH] 7.5 Mg/Ml Solution for Injection Piritramide
    PACKAGE LEAFLET: INFORMATION FOR THE USER Piritramide [MAH] 7.5 mg/ml solution for injection Piritramide Read all of this leaflet carefully before you start using this medicine because it contains important information for you . - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - If you get any side effects , talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Piritramide [MAH] is and what it is used for 2. What you need to know b efore you use Piritramide [MAH] 3. How to use Piritramide [MAH] 4. Possible side effects 5. How to store Piritramide [MAH] 6. Contents of the pack and other information 1. WHAT PIRITRAMIDE [MAH] IS AND WHAT IT IS USED FOR Piritramide [MAH] contains the active substance piritramide. It belongs to a group of medicines called opioid analgesics (strong painkillers). Piritramide [MAH] is used to relieve severe and strongest pain. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE PIRITRAMIDE [MAH] Do not use Piritramide [MAH] : - If you are allergic to piritramide or any of the other ingredients of this medicine (listed in section 6) . - If you suffer from severely impaired consciousness from which you cannot be roused even by external stimuli (comatose states) . - If you have problems with breathing. Warnings and precautions Talk to your doctor or pharmacist before using Piritramide [MAH] - If you have suffer from seizures (such as epileptic fits) - if you suffer from alcoholism - If you have head injuries and/or conditions with increased brain pressure - If you have an enlarged prostate (prostatic hypertrophy) - If you are in shock - you are taking medicines that act on the brain [e.g.
    [Show full text]
  • Procedural Sedation and Analgesia for Percutaneous Trans- Hepatic Biliary
    Open Medicine 2020; 15: 815–821 Research Article Alex Zanvettor, Wolfgang Lederer, Bernhard Glodny, Andreas P. Chemelli, Franz J. Wiedermann* Procedural sedation and analgesia for percutaneous trans- hepatic biliary drainage: Randomized clinical trial for comparison of two different concepts https://doi.org/10.1515/med-2020-0220 patients treated with remifentanil (EudraCT No. 2006- received March 04, 2020; accepted July 17, 2020 003285-34; institutional funding). Abstract: Procedural sedation and analgesia (PSA) is Keywords: biliary tract, cholestasis, procedural sedation, important during painful dilatation and stenting in analgesia, interventional radiology, remifentanil, piri- patients undergoing percutaneous trans-hepatic biliary tramide, midazolam, S-ketamine drainage (PTBD). A prospective, nonblinded randomized clinical trial was performed comparing different an- algesic regimens with regard to the patient’s comfort. Patients were randomly assigned to two treatment 1 Introduction groups in a parallel study, receiving either remifentanil - ( ) or combined midazolam, piritramide, and S-ketamine. Percutaneous trans hepatic biliary drainage PTBD is a The primary study endpoint was pain intensity before, common therapeutic modality in the treatment of biliary during, and after the intervention using the numerical obstruction, in particular when surgical repair is not - rating scale (0, no pain; 10, maximum pain). The practicable and endoscopic retrograde cholangiopan [ ] secondary study endpoint was the satisfaction of the creatography and stenting have failed 1 . In patients ff interventional radiologist. Fifty patients underwent su ering from neoplasms and metastases involving bile PTBD of whom 19 (38.0%) underwent additional ducts and liver tissue, the intervention all too often aims [ ] ffi stenting. During intervention, the two groups did not at palliative treatment 2,3 .
    [Show full text]
  • Postoperative Pain Management in Children
    Accepted: 14 March 2018 DOI: 10.1111/pan.13373 SPECIAL INTEREST ARTICLE Postoperative pain management in children: Guidance from the pain committee of the European Society for Paediatric Anaesthesiology (ESPA Pain Management Ladder Initiative) Maria Vittinghoff1 | Per-Arne Lonnqvist€ 2 | Valeria Mossetti3 | Stefan Heschl1 | Dusica Simic4 | Vesna Colovic5 | Dmytro Dmytriiev6 | Martin Holzle€ 7 | Marzena Zielinska8 | Anna Kubica-Cielinska8 | Elizabeth Lorraine-Lichtenstein9 | Ivana Budic10 | Marijana Karisik11 | Belen De Jose Maria12 | Francesco Smedile13 | Neil S. Morton14 1Department of Anesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria 2Paediatric Anaesthesia & Intensive Care, Section of Anaesthesiology & Intensive Care, Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden 3Department of Anesthesia and Intensive Care, Regina Margherita Children’s Hospital, Torino, Italy 4University Children’s Hospital, Medical Faculty University of Belgrade, Serbia 5Royal Manchester Children’s Hospital, Central Manchester University Hospitals, Manchester, UK 6Department of Anesthesiology and Intensive Care, Vinnitsa National Medical University, Vinnitsa, Ukraine 7Section of Paediatric Anaesthesia, Department of Anaesthesia, Luzerner Kantonsspital, Luzern, Switzerland 8Department of Paediatric Anaesthesiology and Intensive Care, Wroclaw Medical University, Wroclaw, Poland 9Department of Anaesthesia and Intensive Care, Karolinska University Hospital, Huddinge, Sweden 10Centre for Anesthesiology
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2013 (January Update)
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2013 (January update) Afghanistan Oxycodone 43 000 Codeine 50 000 Oxymorphone 300 Dextropropoxyphene 2 000 000 Pethidine 65 000 Diphenoxylate 20 000 Remifentanil 9 100 Fentanyl 6 Sufentanil 1 Methadone 6 000 Thebaine 45 000 Morphine 4 000 Armenia Pethidine 80 000 Codeine 3 000 Pholcodine 100 000 Fentanyl 21 Albania Methadone 10 000 Codeine 35 000 Morphine 4 500 Fentanyl 40 Thebaine 10 Methadone 9 000 Trimeperidine 650 Morphine 3 000 Aruba* Pethidine 2 500 Alfentanil 3 Pholcodine 1 000 Bezitramide 1 Remifentanil 8 Cocaine 70 Sufentanil 1 Codeine 85 Algeria Dextromoramide 1 Alfentanil 500 Dextropropoxyphene 85 Codeine 1 000 000 Fentanyl 130 Etorphine 1 Hydrocodone 2 Fentanyl 1 000 Methadone 150 Morphine 11 000 Morphine 340 Pethidine 3 000 Opium 450 Pholcodine 2 500 000 Oxycodone 26 Sufentanil 30 Pethidine 404 Andorra Piritramide 20 Fentanyl 80 Remifentanil 19 Methadone 1 000 Ascension Island Morphine 500 Alfentanil 1 Oxycodone 1 500 Fentanyl 1 Pethidine 500 Morphine 2 Remifentanil 4 Pethidine 9 Angola* Australia Alfentanil 2 Alfentanil 400 Codeine 30 000 Cannabis 21 500 Dextromoramide 375 Cocaine 20 000 Dihydrocodeine 375 Codeine 9 800 000 Fentanyl 45 Conc. of poppy straw Morphine 11 000 AOA 4 000 000 Pethidine 13 000 ATA 85 000 000 Sufentanil 2 Dextromoramide 10 Anguilla Dextropropoxyphene 1 925 000 Fentanyl 1 Difenoxin 7 Morphine 20 Dihydrocodeine 285 000 Pethidine 300 Diphenoxylate 80 000 Antigua and Barbuda* Ethylmorphine 10 Cocaine 9 Etorphine 2 Codeine 169 Fentanyl 40 000
    [Show full text]
  • Uniform Controlled Substances Act
    CHAPTER 19-03.1 UNIFORM CONTROLLED SUBSTANCES ACT 19-03.1-01. Definitions. As used in this chapter and in chapters 19-03.2 and 19-03.4, unless the context otherwise requires: 1. "Administer" means to apply a controlled substance, whether by injection, inhalation, ingestion, or any other means, directly to the body of a patient or research subject by: a. A practitioner or, in the practitioner's presence, by the practitioner's authorized agent; or b. The patient or research subject at the direction and in the presence of the practitioner. 2. "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser. It does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman. 3. "Anabolic steroids" means any drug or hormonal substance, chemically and pharmacologically related to testosterone, other than estrogens, progestins, and corticosteroids. 4. "Board" means the state board of pharmacy. 5. "Bureau" means the drug enforcement administration in the United States department of justice or its successor agency. 6. "Controlled substance" means a drug, substance, or immediate precursor in schedules I through V as set out in this chapter. 7. "Controlled substance analog": a. Means a substance the chemical structure of which is substantially similar to the chemical structure of a controlled substance in a schedule I or II and: (1) Which has a stimulant, depressant, or hallucinogenic effect on the central nervous system which is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II; or (2) With respect to a particular individual, which the individual represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in schedule I or II.
    [Show full text]
  • Acute Pain and Side Effects After Tramadol in Breast Cancer
    www.nature.com/scientificreports OPEN Acute pain and side efects after tramadol in breast cancer patients: results of a prospective double‑blind randomized study Nikola Besic1*, Jaka Smrekar2 & Branka Strazisar3 The objective of this study was to evaluate the severity of acute pain and side efects in breast cancer patients postoperatively treated with two regimens of tramadol with paracetamol in a prospective double‑blind study. Altogether 117 breast cancer patients who had axillary lymphadenectomy were randomized into two analgesic study groups and the analgesic treatment lasted 4 weeks. Stronger analgesia group received every 8 h 75/650 mg of tramadol with paracetamol, while weaker analgesia group received every 8 h 37.5/325 mg of tramadol with paracetamol. Patients with the higher dose of tramadol had less pain during the 1st and 4th week than patients with the lower dose. Frequency of nausea, vomiting, lymphedema or range of shoulder movement was not signifcantly diferent between the two groups of patients. Constipation was signifcantly more common in the group with stronger analgesia during the 2nd week in comparison to patients with weaker analgesia. The patients who were on 75/650 mg of tramadol with paracetamol had less pain in comparison to patients who were on 37.5/325 mg. Side efects were mild, but common in both groups of patients. Breast surgery is known to cause severe acute postoperative pain in more than 50% of patients 1. Adverse efects were reported even more common afer axillary lymphadenectomy. Gartner et al.2 and Lucci et al.3 reported adverse efects in 70% of patients.
    [Show full text]